Examkin

Question

Difficulty: HardPharmacologic Interventions

A 54-year-old man presents to the emergency department with a 4-day history of fever, pleuritic chest pain, and hemoptysis. He underwent an orthotopic heart transplant 8 months ago for nonischemic cardiomyopathy. His current daily medications include tacrolimus, mycophenolate mofetil, prednisone, and prophylactic valganciclovir. His temperature is 38.6°C (101.5°F), blood pressure is 118/74 mm Hg, pulse is 96/min, and respiratory rate is 20/min. Pulse oximetry shows 94% on room air. Physical examination reveals bronchial breath sounds and inspiratory crackles over the right upper lung field. High-resolution computed tomography of the chest demonstrates a dense right upper lobe consolidation surrounded by a ground-glass opacity (halo sign). Serum galactomannan assay is markedly elevated. Which of the following is the most appropriate pharmacologic management for this patient?

  1. Intravenous voriconazole and decrease the dose of tacrolimusAnswer
  2. B
    Intravenous voriconazole and discontinue mycophenolate mofetil
  3. C
    Intravenous fluconazole and decrease the dose of tacrolimus
  4. D
    Intravenous liposomal amphotericin B and substitute sirolimus for tacrolimus
  5. E
    Intravenous caspofungin and increase the dose of prednisone

Answer

The most appropriate management is to initiate intravenous voriconazole and decrease the dose of tacrolimus.
The patient's clinical presentation, radiologic evidence of a 'halo sign', and positive serum galactomannan assay in the setting of severe immunosuppression are highly specific for invasive pulmonary aspergillosis (IPA). The first-line pharmacologic treatment for IPA is intravenous voriconazole. However, initiating this therapy requires careful medication reconciliation due to a predictable and severe drug-drug interaction. Voriconazole is a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) isoenzyme. Tacrolimus, a calcineurin inhibitor crucial for preventing allograft rejection in this heart transplant recipient, is heavily metabolized by CYP3A4 in the liver and intestines. Concurrent administration of voriconazole without dosage adjustment leads to a drastic and rapid increase in serum tacrolimus concentrations. This supratherapeutic accumulation causes severe calcineurin inhibitor toxicity, manifesting as acute kidney injury, neurotoxicity (e.g., tremors, seizures), and potentially fatal arrhythmias. Therefore, the standard of care when initiating voriconazole is to preemptively decrease the tacrolimus dose (typically by 50% to 75%) and closely monitor trough levels to maintain them within a narrow therapeutic window.

Step-by-Step Solution

1
Diagnose the underlying infection based on clinical and radiographic findings.
The patient has invasive pulmonary aspergillosis.
The classic triad of fever, pleuritic chest pain, and hemoptysis in an immunocompromised host, combined with a CT 'halo sign' and a positive galactomannan assay, is diagnostic.
2
Select the first-line antimicrobial therapy for the diagnosed infection.
Intravenous voriconazole is the standard of care.
Voriconazole provides superior survival outcomes compared to amphotericin B for invasive aspergillosis.
3
Evaluate the patient's current medication list for potential severe drug-drug interactions with the new therapy.
A major interaction exists between voriconazole and tacrolimus.
Voriconazole is a potent inhibitor of CYP3A4, the primary enzyme responsible for metabolizing tacrolimus.
4
Determine the necessary pharmacokinetic intervention to prevent patient harm.
The dose of tacrolimus must be preemptively decreased.
Failing to reduce the tacrolimus dose will lead to supratherapeutic serum levels, causing severe nephrotoxicity and neurotoxicity.

Key Concept

Management of potent CYP3A4 inhibitor interactions with calcineurin inhibitors in solid organ transplant recipients.
Rate this question

Topics

Pharmacologic Interventions

More questions from this topic